Supporting research, development, cosmetic formulation and peptide API programs.
We provide catalog and made-to-order peptide products with inquiry-based quotation, quality documentation and flexible specification confirmation.
Reconstitution and handling reference for 5-Amino-1MQ (10 mg Vial). It sets out how much bacteriostatic water to add, what concentration that produces, how the dose maps onto U-100 syringe units, and how the vial should be stored before and after reconstitution.
High-purity synthetic peptide used in fertility, hormone regulation and peptide-receptor research.
Synthetic oxytocin analog supplied for peptide API research, process development and analytical comparison.
Research peptide used in immune modulation, T-cell function and related cell biology workflows.
Working reference for 5-Amino-1MQ (50 mg Vial). Reconstitution volume and resulting concentration, dose-to-syringe-unit conversion on a U-100 insulin syringe, consumables per protocol length, and storage requirements.
Working reference for Adamax (10 mg Vial). Reconstitution volume and resulting concentration, dose-to-syringe-unit conversion on a U-100 insulin syringe, consumables per protocol length, and storage requirements.
Adipotide (10 mg Vial) is supplied as a lyophilized vial for laboratory research use. This page covers reconstitution volume, the resulting concentration, U-100 syringe equivalents and storage handling.
AICAR (50 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
This reference covers AOD-9604 (2 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
Reconstitution and handling reference for AOD-9604 (5 mg Vial). It sets out how much bacteriostatic water to add, what concentration that produces, how the dose maps onto U-100 syringe units, and how the vial should be stored before and after reconstitution.
Reconstitution and handling reference for Ara-290 (16 mg Vial). It sets out how much bacteriostatic water to add, what concentration that produces, how the dose maps onto U-100 syringe units, and how the vial should be stored before and after reconstitution.
This reference covers BPC-157 (5 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
Handling notes for BPC-157 (10 mg Vial), supplied lyophilized. Covers the reconstitution volume and concentration it yields, U-100 syringe unit equivalents, per-protocol consumable counts and storage conditions.
This reference covers Cagrilintide (5 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
Representative research peptide supplied with flexible purity, scale and documentation options.
Representative TB-500 research peptide inquiry item for distributors and research institutions.
Cosmetic peptide ingredient sample for formulation research and personal care development support.
Cagrilintide (10 mg Vial) is supplied as a lyophilized vial for laboratory research use. This page covers reconstitution volume, the resulting concentration, U-100 syringe equivalents and storage handling.
Handling notes for Cartalax (20 mg Vial), supplied lyophilized. Covers the reconstitution volume and concentration it yields, U-100 syringe unit equivalents, per-protocol consumable counts and storage conditions.
Reconstitution and handling reference for Cerebrolysin (60 mg Vial). It sets out how much bacteriostatic water to add, what concentration that produces, how the dose maps onto U-100 syringe units, and how the vial should be stored before and after reconstitution.
This reference covers Chonluten (20 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
Reconstitution and handling reference for CJC-1295 DAC (2 mg Vial). It sets out how much bacteriostatic water to add, what concentration that produces, how the dose maps onto U-100 syringe units, and how the vial should be stored before and after reconstitution.
CJC-1295 DAC (5 mg Vial) is supplied as a lyophilized vial for laboratory research use. This page covers reconstitution volume, the resulting concentration, U-100 syringe equivalents and storage handling.
This reference covers CJC-1295 NO DAC (5 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
Cortagen (20 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
DSIP (5 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
Reconstitution and handling reference for DSIP (10 mg Vial). It sets out how much bacteriostatic water to add, what concentration that produces, how the dose maps onto U-100 syringe units, and how the vial should be stored before and after reconstitution.
Handling notes for Epitalon (Epithalon) (10 mg Vial), supplied lyophilized. Covers the reconstitution volume and concentration it yields, U-100 syringe unit equivalents, per-protocol consumable counts and storage conditions.
Working reference for FOXO4-DRI (10 mg Vial). Reconstitution volume and resulting concentration, dose-to-syringe-unit conversion on a U-100 insulin syringe, consumables per protocol length, and storage requirements.
Handling notes for GHK-Cu (50 mg Vial), supplied lyophilized. Covers the reconstitution volume and concentration it yields, U-100 syringe unit equivalents, per-protocol consumable counts and storage conditions.
This reference covers GHK-Cu (100 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
Working reference for GHRP-2 (5 mg Vial). Reconstitution volume and resulting concentration, dose-to-syringe-unit conversion on a U-100 insulin syringe, consumables per protocol length, and storage requirements.
Reconstitution and handling reference for GHRP-2 (10 mg Vial). It sets out how much bacteriostatic water to add, what concentration that produces, how the dose maps onto U-100 syringe units, and how the vial should be stored before and after reconstitution.
GHRP-6 (2 mg Vial) is supplied as a lyophilized vial for laboratory research use. This page covers reconstitution volume, the resulting concentration, U-100 syringe equivalents and storage handling.
Reconstitution and handling reference for GHRP-6 (5 mg Vial). It sets out how much bacteriostatic water to add, what concentration that produces, how the dose maps onto U-100 syringe units, and how the vial should be stored before and after reconstitution.
GHRP-6 (10 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
Handling notes for Glutathione (600 mg Vial), supplied lyophilized. Covers the reconstitution volume and concentration it yields, U-100 syringe unit equivalents, per-protocol consumable counts and storage conditions.
This reference covers Gonadorelin (2 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
HCG (5000 IU Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
HGH 191AA (10IU Vial) is supplied as a lyophilized vial for laboratory research use. This page covers reconstitution volume, the resulting concentration, U-100 syringe equivalents and storage handling.
HMG (0.15 mg / 75 IU Vial) is supplied as a lyophilized vial for laboratory research use. This page covers reconstitution volume, the resulting concentration, U-100 syringe equivalents and storage handling.
Working reference for IGF-1 LR3 (1 mg Vial). Reconstitution volume and resulting concentration, dose-to-syringe-unit conversion on a U-100 insulin syringe, consumables per protocol length, and storage requirements.
Ipamorelin (5 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
Working reference for Ipamorelin (10 mg Vial). Reconstitution volume and resulting concentration, dose-to-syringe-unit conversion on a U-100 insulin syringe, consumables per protocol length, and storage requirements.
Kisspeptin (10 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
This reference covers KPV (10 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
L-Carnitine (200 mg Vial) is supplied as a lyophilized vial for laboratory research use. This page covers reconstitution volume, the resulting concentration, U-100 syringe equivalents and storage handling.
Handling notes for Livagen (20 mg Vial), supplied lyophilized. Covers the reconstitution volume and concentration it yields, U-100 syringe unit equivalents, per-protocol consumable counts and storage conditions.
Handling notes for LL-37 (5 mg Vial), supplied lyophilized. Covers the reconstitution volume and concentration it yields, U-100 syringe unit equivalents, per-protocol consumable counts and storage conditions.
This reference covers Mazdutide (5 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
Mazdutide (10 mg Vial) is supplied as a lyophilized vial for laboratory research use. This page covers reconstitution volume, the resulting concentration, U-100 syringe equivalents and storage handling.
Melanotan II (10 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
Reconstitution and handling reference for MGF (5 mg Vial). It sets out how much bacteriostatic water to add, what concentration that produces, how the dose maps onto U-100 syringe units, and how the vial should be stored before and after reconstitution.
This reference covers MOTS-C (5 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
This reference covers MOTS-C (10 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
Reconstitution and handling reference for MOTS-C (20 mg Vial). It sets out how much bacteriostatic water to add, what concentration that produces, how the dose maps onto U-100 syringe units, and how the vial should be stored before and after reconstitution.
MOTS-C (40 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
Reconstitution and handling reference for NAD+ (500 mg Vial). It sets out how much bacteriostatic water to add, what concentration that produces, how the dose maps onto U-100 syringe units, and how the vial should be stored before and after reconstitution.
Handling notes for NAD+ (1000 mg Vial), supplied lyophilized. Covers the reconstitution volume and concentration it yields, U-100 syringe unit equivalents, per-protocol consumable counts and storage conditions.
Neuroxelin (48 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
Ovagen (20 mg Vial) is supplied as a lyophilized vial for laboratory research use. This page covers reconstitution volume, the resulting concentration, U-100 syringe equivalents and storage handling.
Handling notes for Oxytocin (5 mg Vial), supplied lyophilized. Covers the reconstitution volume and concentration it yields, U-100 syringe unit equivalents, per-protocol consumable counts and storage conditions.
Handling notes for Oxytocin (10 mg Vial), supplied lyophilized. Covers the reconstitution volume and concentration it yields, U-100 syringe unit equivalents, per-protocol consumable counts and storage conditions.
This reference covers PE-22-28 (10 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
PEG MGF (2 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
Handling notes for Pinealon (20 mg Vial), supplied lyophilized. Covers the reconstitution volume and concentration it yields, U-100 syringe unit equivalents, per-protocol consumable counts and storage conditions.
This reference covers PNC-27 (30 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
Reconstitution and handling reference for Prostamax (20 mg Vial). It sets out how much bacteriostatic water to add, what concentration that produces, how the dose maps onto U-100 syringe units, and how the vial should be stored before and after reconstitution.
PT-141 (10 mg Vial) is supplied as a lyophilized vial for laboratory research use. This page covers reconstitution volume, the resulting concentration, U-100 syringe equivalents and storage handling.
This reference covers Retatrutide (5 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
Handling notes for Retatrutide (10 mg Vial), supplied lyophilized. Covers the reconstitution volume and concentration it yields, U-100 syringe unit equivalents, per-protocol consumable counts and storage conditions.
Working reference for Retatrutide (20 mg Vial). Reconstitution volume and resulting concentration, dose-to-syringe-unit conversion on a U-100 insulin syringe, consumables per protocol length, and storage requirements.
This reference covers Retatrutide (30 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
Reconstitution and handling reference for Selank (5 mg Vial). It sets out how much bacteriostatic water to add, what concentration that produces, how the dose maps onto U-100 syringe units, and how the vial should be stored before and after reconstitution.
Selank (10 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
Semaglutide (5 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
Semaglutide (10 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
Handling notes for Semaglutide (20 mg Vial), supplied lyophilized. Covers the reconstitution volume and concentration it yields, U-100 syringe unit equivalents, per-protocol consumable counts and storage conditions.
Semax (5 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
Working reference for Semax (10 mg Vial). Reconstitution volume and resulting concentration, dose-to-syringe-unit conversion on a U-100 insulin syringe, consumables per protocol length, and storage requirements.
Working reference for Sermorelin (5 mg Vial). Reconstitution volume and resulting concentration, dose-to-syringe-unit conversion on a U-100 insulin syringe, consumables per protocol length, and storage requirements.
Sermorelin (10 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
SLU-PP-332 (5 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
SNAP-8 (10 mg Vial) is supplied as a lyophilized vial for laboratory research use. This page covers reconstitution volume, the resulting concentration, U-100 syringe equivalents and storage handling.
This reference covers SS-31 (10 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
SS-31 (30 mg Vial) is supplied as a lyophilized vial for laboratory research use. This page covers reconstitution volume, the resulting concentration, U-100 syringe equivalents and storage handling.
Handling notes for SS-31 (50 mg Vial), supplied lyophilized. Covers the reconstitution volume and concentration it yields, U-100 syringe unit equivalents, per-protocol consumable counts and storage conditions.
Survodutide (10 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
TB-500 (5 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
Working reference for TB-500 (10 mg Vial). Reconstitution volume and resulting concentration, dose-to-syringe-unit conversion on a U-100 insulin syringe, consumables per protocol length, and storage requirements.
This reference covers Tesamorelin (5 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
Tesamorelin (10 mg Vial) is supplied as a lyophilized vial for laboratory research use. This page covers reconstitution volume, the resulting concentration, U-100 syringe equivalents and storage handling.
Tesamorelin (20 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
Working reference for Testagen (20 mg Vial). Reconstitution volume and resulting concentration, dose-to-syringe-unit conversion on a U-100 insulin syringe, consumables per protocol length, and storage requirements.
Reconstitution and handling reference for Thymosin Alpha-1 (5 mg Vial). It sets out how much bacteriostatic water to add, what concentration that produces, how the dose maps onto U-100 syringe units, and how the vial should be stored before and after reconstitution.
Reconstitution and handling reference for Thymosin Alpha-1 (10 mg Vial). It sets out how much bacteriostatic water to add, what concentration that produces, how the dose maps onto U-100 syringe units, and how the vial should be stored before and after reconstitution.
Handling notes for Tirzepatide (5 mg Vial), supplied lyophilized. Covers the reconstitution volume and concentration it yields, U-100 syringe unit equivalents, per-protocol consumable counts and storage conditions.
This reference covers Tirzepatide (10 mg Vial) in vial format: reconstitution steps, the concentration each volume produces, syringe-unit conversions and storage conditions for the lyophilized and reconstituted material.
Tirzepatide (15 mg Vial): reconstitution reference for research laboratories. Includes the diluent volume and resulting concentration, syringe-unit conversion, vial and consumable planning, and storage guidance.
Tirzepatide (30 mg Vial) is supplied as a lyophilized vial for laboratory research use. This page covers reconstitution volume, the resulting concentration, U-100 syringe equivalents and storage handling.
Working reference for Vesugen (Lys-Glu-Asp) (20 mg Vial). Reconstitution volume and resulting concentration, dose-to-syringe-unit conversion on a U-100 insulin syringe, consumables per protocol length, and storage requirements.
Vilon (20 mg Vial) is supplied as a lyophilized vial for laboratory research use. This page covers reconstitution volume, the resulting concentration, U-100 syringe equivalents and storage handling.
Product quality and manufacturing consistency are fundamental to all our peptide and biochemical products. Each inquiry can include target purity, scale, packaging and documentation requirements.
HPLC, MS and batch-specific documentation can be discussed for suitable peptide products.
Controlled workflows support repeat supply, batch identification and B2B procurement review.
The inquiry flow captures product, target specification, application and destination details before quotation.